FULVESTRANT (FASLODEX) 250MG/5ML INJECTION 2’S

Faslodex (Fulvestrant) 250mg/5ml Injection

• Indicated as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:

– not previously treated with endocrine therapy, or

– with disease relapse on or after adjuvant antioestrogen therapy, or disease progression on antioestrogen therapy.

• Used in combination with Palbociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.